

Hemophilia Enrollment Form

Fax Referral To: 1-888-280-1191 OR 787-759-4161 Phone: 1-888-280-1190 OR 787-759-4162

Email Referral To: Customer.ServiceFax@CVSHealth.com

Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927

	Complete or include demographic she		Tai		
			DOB		
Address:	DOB: City, State, ZIP Code:				
Gender: Male Female	ony, state, 21 sode				
	none (to primary # provided below) 🗌 Text	(to cell # provided l	pelow) 🗌 Email (to email provided below)		
	able to contact via text or email, Specialty Pl				
• • • • •	······································				
If Minor, Parent/Caregiver/Guard	lian Name (Last, First):				
Relationship to minor:					
Email:	Last Four d	of SSN:	_ Primary Language:		
2 PRESCRIBER INFORMAT	ION				
Prescriber's Name:		_ State License #	·		
Address:	City, S ⁴	ate, ZIP Code:			
Phone: Fax_	Contact Person:		Contact's Phone:		
Diagnosis (ICD-10):	Ship to: 🗌 Patient [Office 🗌 Othe	r:		
D66 Hereditary factor VIII d	-				
D67 Hereditary factor IX de	-				
D68.0 Von Willebrand's dis					
D68.311 Acquired hemophil					
	c disorder due to intrinsic circulatir	ig anticoagulan	ts, antibodies, or inhibitors		
D68.8 Other specified coag	julation defects				
D68.9 Coagulation defect, u	unspecified				
D68.2 Hereditary deficiency	y of other clotting factors				
Other Code:	Description:				
Patient Clinical Information:					
Allergies:	He	eight:in/ci	m Weight:lb/kg		
Nursing:		-			
	nate injection or infusion training/ h	ome health infu	sion nurse visit necessary 🗌 Yes 🗌 No		
	Infusion Clinic 🗌 Outpatient Healt				
	necessary. Date training occurred:				

Reason: MD office training patient Pt already independent Referred by MD to alternate trainer

Hemophilia Enrollment Form

Please complete Patient and Preso	riber information
--	-------------------

Prescriber Phone: Prescriber Phone: Pres	Patient Name:		Patient DOB:	
MEDICATION STRENGT: OOSE & DISECTIONS OUANTITY/REFULS Advate Felse NF ODDizur Image: Contract	Prescriber Name:		Prescriber Phone:	
Advate □ Feiba NF □ Obizur Advate □ Formate □ Inor Advate □ Inor □ Inor □ Inor Approline □ Inor □ Inor □ Inor Occapader Inor □ Inor □ Inor □ Congulator Inor □ Inor □ Inor □ Congulator Inor □ Inor □ Inor □ Inor □ Congulator Inor □ Inor				
Addynoate intervention in the intervention intervention in the intervention interventintervent intervention intervention intervention inter	MEDICATION	STRENGTH		QUANTITY/REFILLS
□ Amicar □ Tablet 500 mg Tablet 1,000 mg Syrup 25% □ Other:	Adynovate Hemofil-M Profilnine Afstyla Humate-P Rebinyn Alphanate Idelvion Recombinate AlphaNine Ixinity Rixubis Alprolix Jivi Thrombate III BeneFIX Koate-DVI Tretten Coagadex Kogenate Vonvendi Corifact Kovaltry Wilate Ceprotin Novoeight Xyntha	IU/kg	Breakthrough Bleed: Infuse units (+/- 10%) slow IV push every hours / days (circle one) for a total of doses as needed for bleeding episodes. Contact your physician's office if bleeding does not resolve. Minor: IU q hr PRN Other: Major: IU q hr PRN Other:	1 mo 3 mo Other: Refills: 1 year
□ IU/kg ortimes per week Breakthrough Bleeding opisodes. Contact your physician's office if bleeding opisodes. Contact your physician's office if bleeding does not resolve. Other:	Amicar	Tablet 1,000 mg	Other:	1 mo 3 mo Other: Refills: 1 year
□ Hemlibra □ 30 mg/mL	Esperoct	IU/kg	or times per week Breakthrough Bleed: IU/kg as needed for bleeding episodes. Contact your physician's office if bleeding does not resolve.	🗌 1 year
□ NovoSeven RT mcg/kg Infusemcg/kg slow IV push everyhours, and/or	- Hemlibra	☐ 60 mg/0.4 mL ☐ 105 mg/0.7 mL	once weekly for 4 weeks Maintenance dose: 1.5 mg/kg subcutaneously every week 3 mg/kg subcutaneously every 2 weeks 6 mg/kg subcutaneously every 4 weeks	☐ 1 mo ☐ 3 mo ☐ Other: Refills: ☐ 1 year
SevenFact Img 75 mcg/kg repeat q 3 hours until hemostasis achieved Quantity: Img Initial dose of 225 mcg/kg. May infuse 9 hours in themostasis not achieved within 9 hours. 9 hours later within 9 hours. For Severe bleeds : 225 mcg/kg, followed if necessary 9 hours later with 75 mcg/kg every 2 hours. 9 hours later with 75 mcg/kg every 2	NovoSeven RT	mcg/kg		1 mo 3 mo Other: Refills: 1 year
Berscriber Signature Required (Stamp Signature Not Allowed) May Substitute / Product Selection Permitted /		☐ 5 mg	 75 mcg/kg repeat q 3 hours until hemostasis achieved or Initial dose of 225 mcg/kg. May infuse 75 mcg/kg q 3 hours prn if hemostasis not achieved within 9 hours. For Severe bleeds : 225 mcg/kg, followed if necessary 6 hours later with 75 mcg/kg every 2 hours. Other Round to nearest whole vial. Weight: kg 	☐ 1 mo ☐ 3 mo ☐ Other: Refills: ☐ 1 year ☐ Other:
"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute / Brand Medically Necessary / Do Not Substitute / No Substitution / Substitution Permissible			Ancillary supplies and kits provide	
DAW / May Not Substitute Substitution Permissible	6 PRESCRIBER SIGNAT	URE REQUIRED (STAMP SIGNATURE NOT ALLOW	ED)
		ubstitute / No Substitution /	,	
		Date:		Date:
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" ATTN: New York and Iowa providers, please submit electronic prescri				

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

©2022 CVS Pharmacy, Inc or one of its affiliates. 75-37166A 02/07/22

Hemophilia Enrollment Form

	ase complete Patient and Prescriber information Patient DOB:	
INFORMATIO	N	
STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
150 mcg	 Weight <50 kg: Single spray in one nostril Weight >50 kg: Single spray in each nostril (2 sprays total) Other: 	Quantity: 1 mo 3 mo Other: Refills: 1 year Other:
Other:	Access Device: Port PICC PIV Butterfly Other: mL every	Quantity: 1 mo 3 mo Other: Refills: 1 year Other:
10 IU/mL 100 IU/mL	Access Device: Port PICC PIV Butterfly Other: mL every	Quantity: 1 mo 3 mo Other: Refills: 1 year Other:
LIES ROUT	DOSE/STRENGTH/DIREC	TIONS
	Catheter Care/Flush – Only on drug admin days – SA and patency	
IV	PIV – NS 5 mL (Heparin 10 units/mL 3-5 mL if multip PORT/PICC – NS 10 mL & Heparin 100 units/mL 3-5 to access port a cath	
Oral PO		
	PORT/PICC – NS 10 mL & Heparin 100 units/mL 3-5 to access port a cath 12.25 mg/kg (0-30 kg) 25 mg 50 mg (Over 30 kg) 1 mg/kg (under 15 kg)	mL, and/or 10 mL sterile saline
e Oral PO	PORT/PICC – NS 10 mL & Heparin 100 units/mL 3-5 to access port a cath 12.25 mg/kg (0-30 kg) 25 mg 50 mg (Over 30 kg) 1 mg/kg (under 15 kg) 12.5-50 mg (15-30 kg) 25 mg 50 mg (Over 30 kg)	mL, and/or 10 mL sterile saline
e Oral PO	PORT/PICC – NS 10 mL & Heparin 100 units/mL 3-5 to access port a cath 12.25 mg/kg (0-30 kg) 25 mg 50 mg (Over 30 kg) 1 mg/kg (under 15 kg) / 12.5-50 mg (15-30 kg) 25 mg 50 mg (Over 30 kg) // 12.5-50 mg (15-30 kg) // 25 mg // 50 mg (Over 30 kg) // 12.5-50 mg (15-30 kg) // 95 mg // 12.5-50 mg (15-30 kg) // 95 mg // 12.5-50 mg (15-30 kg) // 96 mg (0 ver 30 kg) // 12.5-50 mg (15-30 kg) // 97 mg (0 ver 30 kg) // 98 mg (0 ver 30 kg) // 98 mg (0 ver 30 kg) // 98 mg (0 ver 30 kg) // 90 mg (0 ver 30 kg)	mL, and/or 10 mL sterile saline
POral PO	PORT/PICC – NS 10 mL & Heparin 100 units/mL 3-5 to access port a cath 12.25 mg/kg (0-30 kg) 25 mg 50 mg (Over 30 kg) 1 mg/kg (under 15 kg) 12.5-50 mg (15-30 kg) 25 mg 50 mg (Over 30 kg) 25 mg 50 mg (Over 30 kg) Adult 1:1000, 0.3 mL (>30 kg/>66 lbs) Peds 1:2000, 0.3 mL (15-30 kg/33-66 lbs) Infant 0.1 mL/0.1 mL, 0.1 mL (7.5-15 kg/16.5-33 lb PRN severe allergic reaction – Call 911 May repeat in 5-15 minutes as needed Other:	mL, and/or 10 mL sterile saline
	I INFORMATIO STRENGTH 150 mcg Other: Other:	Prescriber Phone:

6PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

DAW / May Not Substitute Prescriber's Signature:	Date:	Substitution Permissible Prescriber's Signature:	Date:
CA. MA. NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution"		ATTN: New Yerk and Jawa menuida	rs. please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

©2022 CVS Pharmacy, Inc or one of its affiliates. 75-37166A 02/07/22